Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function

Biological Psychiatry

Volumn 75, Issue 5, 2014, Pages

  Demjaha, Arsime ^a,b   Egerton, Alice ^a,b   Murray, Robin M ^a   Kapur, Shitij ^a   Howes, Oliver D ^a,b   Stone, James M ^c   McGuire, Philip K ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT;

AMINO ACID BRAIN LEVEL; ANTERIOR CINGULATE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; HUMAN; LETTER; MEDICATION COMPLIANCE; NEUROIMAGING; PATIENT IDENTIFICATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REMISSION; SCHIZOPHRENIA; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; DIHYDROXYPHENYLALANINE; DOPAMINE; FEMALE; GLUTAMIC ACID; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTONS; SCHIZOPHRENIA;

EID: 84893813097     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.06.011     Document Type: Letter

References (24)

1. J.P. Lindenmayer Treatment refractory schizophrenia Psychiatr Q 71 2000 373 384
2. J.M. Stone, M. Raffin, P. Morrison, and P.K. McGuire Review: The biological basis of antipsychotic response in schizophrenia J Psychopharmacol 24 2010 953 964
3. O. Howes, S. Bose, F. Turkheimer, I. Valli, A. Egerton, and D. Stahl et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: A PET study Mol Psychiatry 2011 885 886
4. O.D. Howes, S.K. Bose, F. Turkheimer, I. Valli, A. Egerton, and L.R. Valmaggia et al. Dopamine synthesis capacity before onset of psychosis: A prospective [18F]-DOPA PET imaging study Am J Psychiatry 2011 1311 1317
5. O.D. Howes, A.J. Montgomery, M.C. Asselin, R.M. Murray, I. Valli, and P. Tabraham et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia Arch Gen Psychiatry 66 2009 13 20
6. J. Hietala, E. Syvalahti, H. Vilkman, K. Vuorio, V. Rakkolainen, and J. Bergman et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia Schizophr Res 35 1999 41 50
7. J. Hietala, E. Syvalahti, K. Vuorio, V. Rakkolainen, J. Bergman, and M. Haaparanta et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients Lancet 346 1995 1130 1131
8. A. Demjaha, R.M. Murray, P.K. McGuire, S. Kapur, and O.D. Howes Dopamine synthesis capacity in patients with treatment-resistant schizophrenia Am J Psychiatry 169 2012 1203 1210
9. A. Egerton, C.A. Chaddock, T.T. Winton-Brown, M.A. Bloomfield, S. Bhattacharyya, and P. Allen et al. Presynaptic dopamine dysfunction in people at ultra-high risk for psychosis: Findings in a second cohort Biol Psychiatry 74 2013 106 112
10. Y. Kumakura, P. Cumming, I. Vernaleken, H.G. Buchholz, T. Siessmeier, and A. Heinz et al. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: An [18F]fluorodopa/positron emission tomography study J Neuroscience 27 2007 8080 8087
11. L.H. Lindstrom, O. Gefvert, G. Hagberg, T. Lundberg, M. Bergstrom, and P. Hartvig et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET Biol Psychiatry 46 1999 681 688
12. S. McGowan, A.D. Lawrence, T. Sales, D. Quested, and P. Grasby Presynaptic dopaminergic dysfunction in schizophrenia: A positron emission tomographic [18F]fluorodopa study Arch Gen Psychiatry 61 2004 134 142
13. A. Meyer-Lindenberg, R.S. Miletich, P.D. Kohn, G. Esposito, R.E. Carson, and M. Quarantelli et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia Nat Neurosci 5 2002 267 271
14. S. Nozaki, M. Kato, H. Takano, H. Ito, H. Takahashi, and R. Arakawa et al. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET Schizophr Res 108 2009 78 84
15. J. Reith, C. Benkelfat, A. Sherwin, Y. Yasuhara, H. Kuwabara, and F. Andermann et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis Proc Nat Acad Sci U S A 91 1994 11651 11654
16. O.D. Howes, J. Kambeitz, E. Kim, D. Stahl, M. Slifstein, and A. Abi-Dargham et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: Meta-analysis of imaging studies Arch Gen Psychiatry 69 2012 776 786
17. A. Egerton, S. Brugger, M. Raffin, G.J. Barker, D.J. Lythgoe, and P.K. McGuire et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia Neuropsychopharmacology 37 2012 2515 2521
18. P. McGuffin, and A. Farmer Polydiagnostic approaches to measuring and classifying psychopathology Am J Med Genet 105 2001 39 41
19. R.R. Conley, and D.L. Kelly Management of treatment resistance in schizophrenia Biol Psychiatry 50 2001 898 911
20. N.C. Andreasen, W.T. Carpenter Jr, J.M. Kane, R.A. Lasser, S.R. Marder, and D.R. Weinberger Remission in schizophrenia: Proposed criteria and rationale for consensus Am J Psychiatry 162 2005 441 449
21. S.W. Provencher Estimation of metabolite concentrations from localized in vivo proton NMR spectra Magn Reson Med 30 1993 672 679
22. J.M. Stone, F. Day, H. Tsagaraki, I. Valli, M.A. McLean, and D.J. Lythgoe et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: Relationship to gray matter volume Biol Psychiatry 66 2009 533 539
23. J. Snyder, and A. Wilman Field strength dependence of PRESS timings for simultaneous detection of glutamate and glutamine from 1.5 to 7T J Magn Reson 203 2010 66 72
24. D.C. Javitt Glutamate as a therapeutic target in psychiatric disorders Mol Psychiatry 9 2004 984 997